World Journal of Pharmaceutical
and Medical Research

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical and Medical Research and Technology
An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)
ISSN 2455-3301
IMPACT FACTOR: 6.842

ICV : 78.6

Login Register
World Journal of Pharmaceutical and Medical Research (WJPMR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Indian Science Publications , Cosmos Impact Factor , Research Bible, Fuchu, Tokyo. JAPAN , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , International Innovative Journal Impact Factor (IIJIF) , Scientific Journal Impact Factor (SJIF) , Global Impact Factor (In Process) , Digital Online Identifier-Database System (DOI-DS) , Science Library Index, Dubai, United Arab Emirates , Eurasian Scientific Journal Index (ESJI) , International Scientific Indexing, (ISI) UAE , IFSIJ Measure of Journal Quality , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

SJIF Impact Factor: 6.842

Abstract

RITUXIMAB IN STEROID RESISTANT CHILDHOOD PEMPHIGUS

Dr. Sharmila Patil*, Dr. Ratnakar Shukla, Dr. Sheena Kapoor and Dr. Mamta Kamath

ABSTRACT

Pemphigus vulgaris is an autoimmune vesico-bullous disorder involving the skin and mucous membrane characterized by painful erosions in the mucosae as well as flaccid vesiculo bullae on the skin. Pemphigus can affect all age group. The exact prevalence of paediatric pemphigus is unknown, but probably it affects 1.4 – 3.7% of total cases of pemphigus.[1][2][3] Rituximab is increasingly used in adult patients with pemphigus vulgaris who are nonresponders to conventional line of therapy.[4] However there is limited clinical data on safety and efficacy of rituximab in the paediatric age group. Here, we report a 15-year-old boy of pemphigus vulgaris who was treated with rituximab and achieved complete remission.

[Full Text Article]    [Download Certificate]

Powered By WJPMR | All Right Reserved

WJPMR